Brief: Roivant And Kinevant Sciences Complete Enrollment In RESOLVE-Lung, A Phase 2 Study Evaluating Namilumab
25/04/2024 13:57
April 25 (Reuters) - Roivant Sciences Ltd ROIV.O :
* ROIVANT AND KINEVANT SCIENCES COMPLETE ENROLLMENT IN
RESOLVE-LUNG, A PHASE 2 STUDY EVALUATING NAMILUMAB FOR CHRONIC
PULMONARY SARCOIDOSIS
* ROIVANT SCIENCES LTD - TOPLINE RESULTS ARE EXPECTED BY END
OF
CALENDAR YEAR 2024
Source text for Eikon: ID:nBw9pvJnla
Further company coverage: ROIV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roivant Sciences
See all newsU.S. STOCKS ON THE MOVE-Thermo Fisher, CME, Capital One, Northern Trust
Roivant rises as drug succeeds in two late-stage trials for eye disease
Immunovant falls after lupus drug setback
Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple